Fig. 2

Tumour response to fluorouracil and oxaliplatin in colorectal cancer patients with Type A MSI^+/− tumours. The diameters of metastatic liver lesions were measured in each patient who underwent first-line mFOLFOX6 or CAPOX, and the maximal changes from the initial size were compared and shown as a waterfall plot. Each bar represents the maximal relative change in the tumour size in each patient and is coloured according to the MSI status (Type A MSI⁺, red; Type A MSI^-, blue) and chemotherapy regimen (mFOLFOX6, dark; CAPOX, light). The cut-offs for significant response and disease progression, indicated by dashed horizontal lines, are ≥ 30% decrease and ≥ 20% increase, respectively, which are based on the RECIST version 1.1. Data of Patient F06, who had an unexpected early severe adverse event, is not included in this figure.